Literature DB >> 4828533

Immunotherapy of malignant melanoma with vaccinia virus.

H H Roenigk, S Deodhar, R St Jacques, K Burdick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4828533

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  14 in total

Review 1.  Oncolytic viruses: From bench to bedside with a focus on safety.

Authors:  Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial.

Authors:  M K Wallack; M Sivanandham; K Ditaranto; P Shaw; C M Balch; M M Urist; K I Bland; D Murray; W A Robinson; L Flaherty; J M Richards; L Rosen; A A Bartolucci
Journal:  Ann Surg       Date:  1997-08       Impact factor: 12.969

Review 3.  The role of immunotherapy in the management of patients with malignant melanoma.

Authors:  J E Goodnight; D L Morton
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

4.  The effect of attenuated vaccinia virus AS strain on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric cancer in rats.

Authors:  S Arakawa; K Fukai
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

5.  The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity.

Authors:  S Greiner; J Y Humrich; P Thuman; B Sauter; G Schuler; L Jenne
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

6.  Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates.

Authors:  P Hersey; A Edwards; A Coates; H Shaw; W McCarthy; G Milton
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

7.  Infection of DBA/2 or C3H/HeJ mice by intraperitoneal injection of vaccinia virus elicits activated macrophages, cytolytic and cytostatic for S91-melanoma tumor cells.

Authors:  R J Natuk; J A Byrne; J A Holowczak
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Immune responses of DBA/2 mice bearing melanoma tumors: cell-mediated immune responses after challenge with vaccinia virus.

Authors:  J A Byrne; M Soloski; J A Holowczak
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 9.  Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Authors:  David H Kirn; Steve H Thorne
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

10.  Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours.

Authors:  C T Hiley; M Yuan; N R Lemoine; Y Wang
Journal:  Gene Ther       Date:  2009-11-05       Impact factor: 5.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.